

Gunjan L Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7170098/publications.pdf>

Version: 2024-02-01

102
papers

2,987
citations

172457

29
h-index

189892

50
g-index

103
all docs

103
docs citations

103
times ranked

4241
citing authors

#	ARTICLE	IF	CITATIONS
1	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Advances, 2022, 6, 1525-1535.	5.2	17
2	Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. Transplantation and Cellular Therapy, 2022, 28, 55.e1-55.e5.	1.2	5
3	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	5.2	12
4	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	1.6	60
5	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 485.e1-485.e6.	1.2	0
6	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	7.0	2
7	Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell, 2022, 40, 590-591.	16.8	70
8	Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough. , 2022, 19, .		0
9	Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8047-8047.	1.6	1
10	African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. Journal of Clinical Oncology, 2022, 40, 8045-8045.	1.6	4
11	Patient preferences for second-line treatment options in diffuse large B-cell lymphoma: A discrete choice experiment.. Journal of Clinical Oncology, 2022, 40, e19558-e19558.	1.6	0
12	Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology, 2022, 40, e20005-e20005.	1.6	0
13	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 546-559.	1.2	16
14	Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. Blood Advances, 2022, 6, 6291-6300.	5.2	11
15	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 289-292.	2.4	4
16	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	7.2	45
17	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematology,the, 2021, 8, e185-e193.	4.6	271
18	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2021, 27, 233-240.	1.2	24

#	ARTICLE	IF	CITATIONS
19	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€‘weekly carfilzomib (45 and 56â€‘mg/m ²) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
20	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. Transplantation and Cellular Therapy, 2021, 27, 438.e1-438.e6.	1.2	11
21	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
22	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	1.3	7
23	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	7.1	63
24	Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Advances, 2021, 5, 2608-2618.	5.2	22
25	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	5.2	59
26	Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discovery, 2021, 2, 577-585.	5.0	44
27	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discovery, 2021, 2, 568-576.	5.0	62
28	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 771.e1-771.e10.	1.2	17
29	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 3271-3271.	1.4	1
30	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	1.4	7
31	Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines. Blood, 2021, 138, 3891-3891.	1.4	1
32	A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood, 2021, 138, 96-96.	1.4	24
33	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 58-65.	2.0	8
34	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 198-200.	0.4	17
35	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Advances, 2020, 4, 4669-4678.	5.2	64
36	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer, 2020, 126, 5077-5087.	4.1	47

#	ARTICLE	IF	CITATIONS
37	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
38	Jettison-MS of Nucleic Acid Species. Journal of the American Society for Mass Spectrometry, 2020, 31, 1641-1646.	2.8	2
39	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 2020, 10, 79.	6.2	137
40	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 2020, 4, 3776-3787.	5.2	162
41	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
42	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. Blood Advances, 2020, 4, 6064-6076.	5.2	29
43	Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric Antigen receptor (CAR) T cell therapy. British Journal of Haematology, 2020, 190, 45-51.	2.5	51
44	Infectious Complications in Aggressive B Cell Non-Hodgkin Lymphoma after CD-19 Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, S326.	2.0	3
45	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Advances, 2020, 4, 3024-3033.	5.2	75
46	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2020, 382, 822-834.	27.0	435
47	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine, 2020, 23, 1653-1657.	1.1	1
48	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances, 2020, 4, 676-686.	5.2	101
49	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
50	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. Journal of Clinical Investigation, 2020, 130, 6656-6667.	8.2	101
51	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0
52	Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants. Blood, 2020, 136, 4-4.	1.4	0
53	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	1.4	0
54	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. Blood, 2020, 136, 1-2.	1.4	1

#	ARTICLE	IF	CITATIONS
55	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
56	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
57	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 26-28.	1.4	2
58	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
59	Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121711.	2.3	9
60	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	7.2	26
61	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1526-1535.	2.0	15
62	Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S38-S39.	2.0	4
63	Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 41-46.	2.0	15
64	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.	2.0	7
65	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
66	Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs. <i>Blood</i> , 2019, 134, 793-793.	1.4	22
67	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	1.4	34
68	Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 125-134.	2.3	18
69	Transplant strategies in relapsed/refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1689-1697.	1.4	36
70	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 871-876.	2.0	35
71	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. <i>Leukemia and Lymphoma</i> , 2018, 59, 1981-1985.	1.3	16
72	Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. <i>Bone Marrow Transplantation</i> , 2018, 53, 1184-1187.	2.4	21

#	ARTICLE	IF	CITATIONS
73	Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 425-432.	2.0	15
74	Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 142-149.	2.0	16
75	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 133-141.	2.0	11
76	Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S323-S324.	2.0	1
77	Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2517-2522.	2.0	13
78	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	0.4	20
79	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	1.4	9
80	Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in the Modern Era. <i>Blood</i> , 2018, 132, 2148-2148.	1.4	1
81	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959.	1.4	71
82	Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers. <i>Blood</i> , 2018, 132, 2258-2258.	1.4	2
83	Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma. <i>Blood</i> , 2018, 132, 4617-4617.	1.4	1
84	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1823-1831.	1.3	57
85	Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S142-S143.	2.0	1
86	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+â€Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2004-2011.	2.0	11
87	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.	1.7	3
88	Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1215-1228.	2.2	2
89	Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 175, 440-447.	2.5	27
90	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015, 125, 1866-1869.	1.4	32

#	ARTICLE	IF	CITATIONS
91	The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Journal of the National Cancer Institute, 2015, 107, .	6.3	29
92	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Resultsâ€“Medicare Database. Biology of Blood and Marrow Transplantation, 2015, 21, 1823-1829.	2.0	30
93	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 2160-2166.	2.0	31
94	Incidence and Evaluation of Incidental Abnormal Bone Marrow Signal on Magnetic Resonance Imaging. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	9
95	Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients. Clinical Therapeutics, 2013, 35, 1614-1620.	2.5	18
96	Mitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature. Case Reports in Hematology, 2013, 2013, 1-3.	0.4	11
97	Abnormal bone marrow signal on MRI heralding oncologic diagnoses: A single institution review.. Journal of Clinical Oncology, 2013, 31, 1580-1580.	1.6	1
98	Cost-Implications Of Comorbidity For Autologous Hematopoietic Stem Cell Transplantation (Auto) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 122, 1746-1746.	1.4	1
99	Plerixafor and G-CSF For Autologous Stem Cell Mobilization In AL Amyloidosis: A Single Center Experience. Blood, 2013, 122, 4516-4516.	1.4	0
100	What Intensivists Need to Know About Hemophagocytic Syndrome. Journal of Intensive Care Medicine, 2012, 27, 58-64.	2.8	35
101	Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.. Blood, 2012, 120, 2968-2968.	1.4	5
102	Absolute Lymphocyte Count As Predictor of Survival Following Hematopoietic Stem Cell Transplants. Blood, 2011, 118, 4538-4538.	1.4	0